CLOs on the Move

R1 RCM

www.r1rcm.com

 
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers R1`s proven and scalable operating models seamlessly complement a healthcare organization`s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.r1rcm.com
  • 434 West Ascension Way 6th Floor
    Murray, UT USA 84123
  • Phone: 312.324.7820

Executives

Name Title Contact Details
Corey Perman
Executive Vice President of Compliance and Risk Profile
John Blair
Vice President, IT Security and Risk Profile
Carrie Palmer
Vice President, Assistant General Counsel Profile
Trevor Torrence
Director, Legal Operations Profile

Similar Companies

Giving Home Health Care

We provide in-home health care for those with illnesses contracted while working in nuclear energy programs.

Kyowa Kirin

Kyowa Kirin Co., Ltd.

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

Louisiana Wholesale Drug Company

Louisiana Wholesale Drug Company is a Ruston, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.